Click Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more

Getty Images With Sanofi still on board, Click Therapeutics closes $52M series B for digital therapeutics in depression, chronic pain and more (Fierce Biotech): Another medtech developer’s plans to create digital therapeutics to treat a wide range of illnesses are clicking into place, thanks to a third multimillion-dollar investment in Click Therapeutics in barely a year. Click has already validated and begun the commercial launch of its first product, Clickotine, a mobile software program for smoking cessation … Several more of Click’s app-based therapeutics—all of which will require a physician’s prescription and therefore FDA clearance—are undergoing clinical trials and run the gamut of medical targets. The furthest along of these is a program to treat major depressive disorder, developed in partnership with Otsuka. A phase 3 trial of the program hosted on Verily’s Baseline platform is now studying the abilities of several cognitive exercises to lessen the symptoms of depression. Close behind in phase 2 trials are Click’s work to treat migraine and schizophrenia—the latter of which is a collaboration with Boehringer Ingelheim—as well as the cleverly named Clickadian, for insomnia, and Clickheart, for acute coronary syndrome. Digital therapeutics for overactive bladder, chronic lower back pain and obesity, meanwhile, are still in the earliest stages of clinical study. The Announcement: Click Therapeutics Completes $52 Million Series B Financing Co-Led by...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Brain/ Mental Health Technology & Innovation acute coronary syndrome app-based therapeutics chronic pain Click Therapeutics Clickadian Clickheart Clickotine cognitive cognitive-exercises depression digital therapeutics FDA cleara Source Type: blogs